Fund Seeks New Board Members for Orchid Cellmark | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accipiter Life Sciences Fund last week informed Orchid Cellmark that it will nominate three individuals to serve on the DNA testing company's board of directors — a move that would effectively replace the three Class I directors of the current board, according to a filing with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.